검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CRISPR/Cas9 (CRISPR/Cas9) Allife Medical Science and Technol…·Human Papillomavirus-Related Malig… ORR 25% |
|---|---|
Overview Program | CRISPR/Cas9 |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Human Papillomavirus-Related Malignant N |
Overview Indication | Human Papillomavirus-Related Malignant Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25.0% |
Clinical Result source | ClinicalTrials.gov NCT04035434 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CRISPR/Cas9 (CRISPR/Cas9) Allife Medical Science and Technol…·Human Papillomavirus-Related Malig… ORR 25% |
|---|---|
Overview Program | CRISPR/Cas9 |
Overview Company | Allife Medical Science and Technology Co., Ltd. |
Overview Modality | CGT |
Overview Target | Human Papillomavirus-Related Malignant N |
Overview Indication | Human Papillomavirus-Related Malignant Neoplasm |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen |
MoA Biomarker | PD-L1 therapy, reduced CD8 + T-cell infiltration, and attenuated MHC-I expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biotechnological strategies to combat antibiotic resistance.. This article aims to present the current state of knowledge on four major biotechnological antimicrobial strategies and to evaluate their potential clinical applications in the context of increasing antibiotic resistance. Approaches such as phage therapy, CRISPR-Cas9 gene editing, nanoparticles, and antimicrobial peptides (AMPs) may sig… |
Clinical Primary efficacy | ORR 25% |
Clinical ORR | 25.0% |
Clinical Result source | ClinicalTrials.gov NCT04035434 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교